Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
|
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 50 条
  • [1] Renal Toxicities of Targeted Therapies
    Anum Abbas
    Mohsin M. Mirza
    Apar Kishor Ganti
    Ketki Tendulkar
    Targeted Oncology, 2015, 10 : 487 - 499
  • [2] Renal Toxicities of Targeted Therapies
    Abbas, Anum
    Mirza, Mohsin M.
    Ganti, Apar Kishor
    Tendulkar, Ketki
    TARGETED ONCOLOGY, 2015, 10 (04) : 487 - 499
  • [3] Renal toxicities of targeted therapies in oncology
    Izzedine, Hassan
    NEPHROLOGIE & THERAPEUTIQUE, 2020, 16 (01): : 1 - 8
  • [4] Advances in the Management of Cutaneous Toxicities of Targeted Therapies
    Robert, Caroline
    Sibaud, Vincent
    Mateus, Christine
    Cherpelis, Basil S.
    SEMINARS IN ONCOLOGY, 2012, 39 (02) : 227 - 240
  • [5] Selected Toxicities of Targeted Therapies: Presentation and Management
    Kollmannsberger, Christian
    Mitchell, Teresa
    SEMINARS IN ONCOLOGY, 2013, 40 (04) : 499 - 510
  • [6] Toxicities of new targeted therapies in renal carcinoma.
    Cortes, M. N.
    Richardet, E.
    Richardet, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
    Alasker, Ahmed
    Meskawi, Malek
    Sun, Maxine
    Ismail, Salima
    Hanna, Nawar
    Hansen, Jens
    Tian, Zhe
    Bianchi, Marco
    Perrotte, Paul
    Karakiewicz, Pierre I.
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 388 - 401
  • [8] Management of targeted molecular therapies toxicities in thoracic cancerology
    Rajpar, S.
    Osio, A.
    Besse, B.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2008, 64 (02) : 104 - 110
  • [9] Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
    Lacouture, Mario E.
    CANCER NURSING, 2007, 30 (04) : S17 - S26
  • [10] Management of side effects of targeted therapies in renal cancer: sexual disorders
    Bessede, Thomas
    Joly, Florence
    Lebret, Thierry
    BULLETIN DU CANCER, 2011, 98 : S127 - S131
12345